Drug intelligence / Profile preview

SOR104

Development stage: Preclinical
Lead developer: Sorriso Pharmaceuticals
Modality: Small Molecules, Antibody-Based Therapeutics
Administration: Oral

Overview

SOR104 is an oral antibody therapy developed by Sorriso Pharmaceuticals. It is an anti-IL-7Rα Vorabody designed to block signaling mediated by interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP), both of which are implicated in immune-mediated diseases. By inhibiting IL-7Rα, SOR104 aims to modulate immune responses involved in inflammatory and autoimmune conditions. The drug represents a novel approach as an orally administered antibody targeting cytokine signaling pathways[1][2].

Targets

IL7R (Interleukin-7 Receptor)TSLPR (TSLP receptor)

Beyond the preview

Go deeper on SOR104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOR104.